EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)Open Access

Finerenone in Patients With Chronic Kidney Disease Due to Glomerular Diseases

Brendon L Neuen, Vlado Perkovic, Rajiv Agarwal, David Z I Cherney, Carolyn S P Lam, Christoph Wanner, Katherine R Tuttle, Pantelis Sarafidis, Jonathan Barratt, Anna Burgner, Xiangmei Chen, Alfredo Chew-Wong und 24 weitere

JAMA · 21.07.2026 · 336 (3) · 224

DOI: 10.1001/jama.2026.9923 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA, erschienen am 21.07.2026. Verfasst von Brendon L Neuen und 35 weiteren Autor:innen. Beteiligte Einrichtung: The George Institute for Global Health, University of New South Wales, Sydney, Australia. Hauptthemen laut MEDLINE: Albuminuria, Glomerulonephritis, Mineralocorticoid Receptor Antagonists, Naphthyridines. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Glomerular diseases are a leading cause of chronic kidney disease (CKD) and kidney failure. Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, reduces the risk of kidney function loss in CKD, but its effects in individuals with CKD due to glomerular diseases are uncertain.

Objectives

To evaluate the efficacy and safety of finerenone in patients with glomerular diseases. Design, Setting, and Participants Prespecified exploratory subgroup analysis of a phase 3, randomized, double-blind, placebo-controlled trial conducted across 24 countries and regions, focusing on participants with an investigator-reported glomerular disease diagnosis. The overall trial enrolled adults with nondiabetic CKD and an estimated glomerular filtration rate (eGFR) of either (1) at least 25 to less than 60 mL/min/1.73 m 2 and urinary albumin to creatinine ratio of at least 200 mg/g to less than 500 mg/g or (2) an eGFR of at least 25 to less than 90 mL/min/1.73 m 2 and urinary albumin to creatinine ratio of at least 500 mg/g to less than 3500 mg/g.

Intervention

Finerenone 10 mg or 20 mg taken orally once daily (n = 446) vs matching placebo (n = 457). Main Outcomes and Measures Annualized rate of eGFR decline (total eGFR slope) from baseline to month 32 (primary outcome of the main trial); percent change in albuminuria to 12 months; and a composite outcome of kidney failure or sustained 40% or more decline in eGFR (prespecified exploratory outcomes).

Results

Of 1584 participants, 903 (57.0%) had investigator-reported glomerular disease, including 416 (46.1%) with immunoglobulin A nephropathy, 215 (23.8%) with focal segmental glomerulosclerosis, and 90 (10.0%) with membranous nephropathy. Participants with glomerular disease (mean [SD] age, 51.1 [13.6] years; 362 female [40.1%]; 558 Asian [61.9%]) had a mean eGFR of 48.8 mL/min/1.73 m 2 and median urinary albumin to creatinine ratio of 839.6 mg/g. The total eGFR slope up to 32 months was −3.50 mL/min/1.73 m 2 per year with finerenone and −4.23 mL/min/1.73 m 2 per year with placebo (0.73 mL/min/1.73 m 2 per year difference; 95% CI, 0.22-1.24). Finerenone reduced albuminuria at month 12 by 42% (95% CI, 35%-48%) and lowered the risk of kidney failure or 40% or more eGFR decline (7.42 vs 9.60 events per 100 patient-years; hazard ratio, 0.74; 95% CI, 0.57-0.97). Conclusions and Relevance In this exploratory analysis, treatment with finerenone slowed kidney function decline, reduced albuminuria, and lowered the risk of kidney failure or substantial loss of kidney function in patients with glomerular diseases. These findings suggest an important role for finerenone in preserving kidney function in this population. Trial Registration ClinicalTrials.gov Identifier: NCT05047263

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AlbuminuriaGlomerulonephritisMineralocorticoid Receptor AntagonistsNaphthyridinesRenal Insufficiency, ChronicAdultAgedFemaleHumansMaleMiddle AgedCreatinineDouble-Blind MethodGlomerular Filtration RateGlomerulosclerosis, Focal SegmentalGlomerulonephritis, IGAGlomerulonephritis, MembranousTreatment Outcome

Substanzen

CreatininefinerenoneMineralocorticoid Receptor AntagonistsNaphthyridines

Autor:innen und Institutionen

  • The George Institute for Global Health, University of New South Wales, Sydney, Australia.
  • Department of Renal Medicine, Royal North Shore Hospital, Sydney, New South Wales, Australia.
  • University of New South Wales, Sydney, Australia.
  • Division of Nephrology, Richard L. Roudebush VA Medical Center and Indiana University School of Medicine, Indianapolis.
  • Division of Nephrology, University Health Network, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada.
  • National Heart Centre Singapore, Singapore, Singapore.

Zitieren

APA

Neuen, B. L., Perkovic, V., Agarwal, R., Cherney, D. Z. I., Lam, C. S. P., Wanner, C., Tuttle, K. R., Sarafidis, P., Barratt, J., Burgner, A., Chen, X., Chew-Wong, A., Dobronravov, V. A., Floege, J., McCafferty, K., Nangaku, M., Packham, D., Papachristou, E., Pergola, P. E., …, & FIND-CKD Investigators (2026). Finerenone in Patients With Chronic Kidney Disease Due to Glomerular Diseases. JAMA, 336(3), 224. https://doi.org/10.1001/jama.2026.9923

Vancouver

Neuen BL, Perkovic V, Agarwal R, Cherney DZI, Lam CSP, Wanner C, et al. Finerenone in Patients With Chronic Kidney Disease Due to Glomerular Diseases. JAMA. 2026;336(3):224. doi:10.1001/jama.2026.9923

BibTeX
@article{Neuen2026,
  author = {Neuen, Brendon L and Perkovic, Vlado and Agarwal, Rajiv and Cherney, David Z I and Lam, Carolyn S P and Wanner, Christoph and Tuttle, Katherine R and Sarafidis, Pantelis and Barratt, Jonathan and Burgner, Anna and Chen, Xiangmei and Chew-Wong, Alfredo and Dobronravov, Vladimir A and Floege, Jürgen and McCafferty, Kieran and Nangaku, Masaomi and Packham, David and Papachristou, Evangelos and Pergola, Pablo E and Speeckaert, Marijn M and Subbiah, Arunkumar and Tang, Sydney C W and Tang, Shuifu and Yeo, See Cheng and Jongs, Niels and Smeijer, J David and Berger, Mario and Brinker, Meike and Dayoub, Rania and Elliott, Jay and Li, Na and Mueller, Katharina and Rethemeier, Nicole and Finkelsztein, Marina Yael and Heerspink, Hiddo J L and FIND-CKD Investigators, FIND-CKD Investigators},
  title = {Finerenone in Patients With Chronic Kidney Disease Due to Glomerular Diseases},
  journal = {JAMA},
  year = {2026},
  volume = {336},
  number = {3},
  pages = {224},
  doi = {10.1001/jama.2026.9923}
}
Kostenlos starten →